Brief: Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform

CervoMed

18/02/2026 11:10

Feb 18 (Reuters) - CervoMed Inc CRVO.O:

CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED TO PRIORITIZE PROMISING TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS

CERVOMED INC - FIRST ALS PATIENT EXPECTED TO BE DOSED BY END OF 2026

CERVOMED: MAINTAIN FOCUS ON DLB, TAKE STEPS TO INITIATE PLANNED PHASE 3 TRIAL LATER THIS YEAR

Source text: ID:nGNX2TdN7K

Further company coverage: CRVO.O

 ((Reuters.Briefs@thomsonreuters.com;))